Executive Vice President of Research and Development, Chief Medical Officer · Supernus Pharmaceuticals, Inc. (SUPN)

Stefan Schwabe

A named executive officer of Supernus Pharmaceuticals in every fiscal year CompBrief holds from FY2016 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,189,554

Salary $413,001Stock awards $0

FY2019: $1,469,056

3rd of 6 named executive officers at Supernus Pharmaceuticals by FY2020 total.

6 named officers on file for Supernus Pharmaceuticals, FY2020

Stefan Schwabe’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • SUPN’s disclosed peer group of 29 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Supernus Pharmaceuticals’s whole pay program stands against its peers

  • Supernus Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SUPN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2021 (DEF 14A).

Free

Get Stefan Schwabe’s full pay file as a PDF — free

More than this page: up to 10 years of Stefan’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Stefan Schwabe compensation by year

Supernus Pharmaceuticals Summary Compensation Table · all 5 fiscal years held
In US dollars, as Supernus Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020
Salary$366,583$378,000$389,500$401,175$413,001
Bonus$0$0$0$0$0
Stock awards$0$0$0$0$0
Option awards$353,530$679,776$695,815$885,020$703,268
Non-equity incentive$159,000$159,000$163,000$150,900$0
Pension and deferred compensation$0$0$0$0$0
All other$44,046$31,606$30,384$31,961$73,284
Total$923,159$1,248,382$1,278,699$1,469,056$1,189,554

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Supernus Pharmaceuticals, Inc. DEF 14A filed April 30, 2021, accession 0001104659-21-058739, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Supernus Pharmaceuticals, Inc. filed document, accession 0001104659-21-058739. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2021.

$923K
$1.2M
$1.3M
$1.5M
$1.2M
FY16
FY17
FY18
FY19
FY20
SalaryNon-equity incentiveOption awardsAll other

Supernus Pharmaceuticals’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Jack KhattarChief Executive Officer, President & Secretary$6,669,046
James KellyFormer Executive Vice President, Chief Financial Officer$1,801,636
Stefan Schwabe · this pageExecutive Vice President of Research and Development, Chief Medical Officer$1,189,554
Gregory PatrickSenior Vice President, Chief Financial Officer$1,152,802
Padmanabh BhattSenior Vice President, Intellectual Property, Chief Scientific Officer$1,074,490
Tami MartinSenior Vice President, Regulatory Affairs$804,637

The full Supernus Pharmaceuticals compensation record

free company brief

This page is one person within Supernus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Supernus Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Supernus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Stefan Schwabe's compensation dossier · One-time report. No refunds.